Pharma channel feed

Pfiz­er ex­pects few­er peo­ple need­ed for Ly­me dis­ease vac­cine tri­al

Last year
R&D

Apel­lis' safe­ty probe in­to eye drug un­earths is­sues with in­jec­tion kits, while side ef­fects re­main 'very rare'

Last year
R&D

Re­searchers sug­gest new meth­ods to fi­nance pe­di­atric can­cer R&D — Na­ture pa­per

Last year

Boehringer In­gel­heim files suit to block drug price ne­go­ti­a­tions. Is the fight ul­ti­mate­ly head­ed for the Supreme Court?

Last year

Gov­ern­ment pan­el of­fers strongest rec­om­men­da­tion for PrEP to pre­vent HIV

Last year

FDA warns Ama­zon and Wal­mart over sale of un­ap­proved prod­uct

Last year
FDA+

UK in­vests $13M+ in 17 bio­phar­ma man­u­fac­tur­ers

Last year
Manufacturing

Op­er­a­tion Warp Speed re­dux: HHS awards $1.4B to de­vel­op next-gen Covid-19 drugs and vac­cines

Last year
FDA+

Bay­er's new busi­ness unit teams up with Ma­hana Ther­a­peu­tics to com­mer­cial­ize dig­i­tal treat­ments

Last year

CMS lays out how se­niors can pay for drugs on a month­ly ba­sis in 2025 and be­yond

Last year
FDA+

Hori­zon, Roche top list for phar­ma rep­u­ta­tion among rare dis­ease pa­tient groups, sur­vey finds

Last year
Marketing

Mar­ket­ingRx roundup: Alzheimer’s As­so­ci­a­tion rais­es aware­ness in His­pan­ic com­mu­ni­ty; Can­cer re­search fundrais­er tops $795M

Last year
Marketing

In­ver­sa­go was work­ing to­ward a po­ten­tial 2024 IPO, but No­vo’s in­ter­est won out. CB1 biotechs hope to ride the wave

Last year
Deals
In Focus

Te­va agrees to pay $225M in fines to set­tle DOJ charges of price-fix­ing gener­ic drugs

Last year

Pfiz­er's ma­ter­nal RSV vac­cine ap­proved to help pro­tect new­borns

Last year
FDA+

US Patent and Trade­mark Of­fice to hear patent chal­lenge over ex­per­i­men­tal seizure treat­ment

Last year
Law

Alk­er­mes' $194M pay­ment from Janssen gets ap­proval from court

Last year
Law

FDA sets Oc­to­ber ad­comm to dis­cuss full ap­proval for Am­gen’s Lumakras to treat sec­ond-line lung can­cer

Last year
FDA+

Af­ter two flops, Roche and Ex­elix­is post ear­ly PhI­II win for Tecen­triq/Cabome­tyx com­bo — but will wait for OS da­ta

Last year
R&D

FDA ap­proves high dose of Re­gen­eron's eye treat­ment Eylea in quick bounce­back from June re­jec­tion

Last year
FDA+

Ab­b­Vie ex­plores the emo­tion­al side of rare chron­ic can­cer in on­go­ing CLL video se­ries

Last year
Marketing

FDA ap­proves Re­gen­eron's an­ti­body for rare im­mune dis­ease, re­solves man­u­fac­tur­ing is­sues for afliber­cept

Last year
FDA+

AARP, in am­i­cus brief, ar­gues that CMS ne­go­ti­at­ing drug prices is in the pub­lic in­ter­est

Last year
FDA+

Mul­ti-task­ing doc­tors at home are watch­ing TV and re­search­ing phar­ma ads — on Google and even EMRs, sur­vey finds

Last year
Marketing
First page Previous page 105106107108109110111 Next page Last page
A service from the Financial Times